JPH0536026B2 - - Google Patents
Info
- Publication number
- JPH0536026B2 JPH0536026B2 JP58041846A JP4184683A JPH0536026B2 JP H0536026 B2 JPH0536026 B2 JP H0536026B2 JP 58041846 A JP58041846 A JP 58041846A JP 4184683 A JP4184683 A JP 4184683A JP H0536026 B2 JPH0536026 B2 JP H0536026B2
- Authority
- JP
- Japan
- Prior art keywords
- fraction
- molecular weight
- milk
- royal jelly
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940109850 royal jelly Drugs 0.000 description 22
- 235000013336 milk Nutrition 0.000 description 18
- 239000008267 milk Substances 0.000 description 18
- 210000004080 milk Anatomy 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 210000004102 animal cell Anatomy 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000012258 culturing Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000003169 placental effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 6
- 102000010445 Lactoferrin Human genes 0.000 description 5
- 102000050459 human LTF Human genes 0.000 description 5
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 5
- 235000021242 lactoferrin Nutrition 0.000 description 5
- 229940078795 lactoferrin Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108010063045 Lactoferrin Proteins 0.000 description 4
- 239000007640 basal medium Substances 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
本発明は、動物細胞または動物細胞由来の細胞
を培養する無血清または低タンパク質濃度の培地
に関するものであり、乳および/または乳の成分
を含有することを特徴とする脂肪培養用培地に関
するものである。
動物細胞および動物細胞由来の細胞には、抗
体、インターフエロン、インシユリン、酵素など
の有効物質を産生するものが知られており、その
細胞を培養することによつてこれらの有効物質を
得ることの実施または試みがなされている。従来
よりこれらの細胞を培養するためには、ほとんど
の場合、培地に血清を添加することが必要であ
る。血清としては、一般に牛胎児血清、子牛血清
などが用いられており、添加量は通常10%程度で
ある。しかし、これらの血清は高価であること、
品質が一定しないこと、供給に制限があることな
どの難点がある。また、血清はタンパク質などの
多種多様な成分を含んでいるため、培養物から有
効物質を分離する場合に分離、精製が容易でな
い。
本発明者らは、これらのことを解決すべく研究
を重ねた結果、低タンパク質濃度さらには無血清
の培地で細胞増殖が可能なことを見いだし、本発
明を完成したものである。
乳は、例えば人乳、畜乳(牛、山羊、羊、馬な
ど)であり初乳、成乳を問わず用いることができ
る。乳を遠心して得られる溶液画分(以下乳の遠
心溶液画分と略す)は、乳を例えば2万×gで遠
心して得る。分子量分画は、例えばSephadex G
−200(Pharmacia Fine Chemicals)または
Cellulofine GC−700(生化学工業株式会社)など
を用いるゲルろ過法により行う。そのとき用いる
平衡化および溶出用溶液は、例えばリン酸緩衝化
生理食塩水、100mM Na−Hepes緩衝液(PH
7.4)、水などである。ラクトフエリンは、例えば
Lo¨nnerdalらの方法(Lo¨nnerdal,B.,Carlsson,
J.,and Porath,J.(1977)FEBS Lett.75,89−
92)で精製する。本発明の細胞培養用培地は、こ
れらのものを通常の動物細胞の培養に用いられる
基礎培地(血清を含まない)に添加して用いる。
また、これらの乳および/または乳の成分と、
ローヤルゼリーおよび/またはローヤルゼリーの
成分、胎盤血の分子量5−8万の画分の中より1
種以上を基礎培地に添加して用いることもでき
る。ローヤルゼリーの成分は、以下のようにして
得る。ローヤルゼリーの分子量20万以上の画分お
よび分子量5−8万の画分は、乳の分子量分画と
同様の方法で得ることができる。ローヤルゼリー
の分子量約58000のタンパク質(以下ローヤルゼ
リータンパク質と略す)は、例えば以下のように
して精製する。ローヤルゼリーをリン酸緩衝化生
理食塩水で2倍に希釈後、それに対し透析する。
透析後、2万×gで遠心し、得られる上清を乳の
場合と同様の方法で分子量分画し、5−8万の分
子量画分を得る。この画分を1mM Tris−HCl緩
衝液(PH8.0)に透析後、同様の緩衝液で平衡化
したBlue Sepharose(Pharmacia Fine
Chemicals)にかけ、素通り画分すなわちローヤ
ルゼリータンパク質を得る。また、ヒト胎盤血の
分子量5−8万の画分(以下ヒト胎盤血画分と略
す)については、例えば胎盤から自然にしみ出た
血液を2万×gで遠心し、その上清を更に上記の
方法で分子量分画し得ることができる。
本発明培地の基礎培地としては、一般の動物細
胞の培養に用いられるものであればいかなるもの
も用ることができる。例えば、Dulbecco's
Modified Eagle medium(以下D'MEMと略す)、
F−12、RPMI−1640などの基礎培地、また、こ
れら基礎培地にインシユリン(2−10μg/ml)、
セレニウム(10-11−10-8M)、トランスフエリン
(10−35μg/ml)、核酸前駆体(例えばチミジ
ン、ヒポキサンチンなど、10-6M程度)、血清ア
ルブミン(50−400μg/ml)などを添加した培
地も基礎培地として用いることができる。本発明
の培地に添加する乳は、0.1〜5%(タンパク質
の最終濃度は7−350μg/ml)、好ましくは0.5〜
2%の範囲にすることが望ましい。乳の遠心溶液
画分については7−350μg/ml、分子量20万以
上の画分については1−100μg/ml、分子量4
−9万の画分については1−150μg/mlおよび
ラクトフエリンについては0.5−50μg/mlが望ま
しい。その他のローヤルゼリー、ローヤルゼリー
の成分および胎盤血画分については10−300μ
g/mlであることが望ましい。
本発明培地は、繊維芽細胞、リンパ芽球細胞な
どの動物細胞の培養に用いることもできるが、リ
ンパ球由来細胞などの動物細胞由来の細胞の培養
に最も好適に用いられる。本発明の培地を用いれ
ば血清を大量に添加した従来の培地にほぼ匹敵す
る細胞増殖を得ることができる。そして従来の培
地と比べ、安価であり、特に牛乳および/または
その成分を用いる場合には非常に安く培養が可能
である。また、血清を10%添加した場合の培地中
のタンパク質濃度が3mg/ml以上であるのに比
べ、本発明の培地は0.4mg/ml以下と低タンパク
質濃度であることから、有効物質産生に本発明培
地を用いることにより有効物質の分離、精製が容
易となる。更に、本発明培地は分子量的に分画し
た画分を添加することも可能であることから、有
効物質の分子量により使いわけて用いることもで
きる。例えば抗体(分子量15万以上)を産生する
細胞を培養する場合には、ラクトフエリンおよ
び/または乳の分子量4−9万の画分と、要すれ
ばローヤルゼリーから分離、精製した分子量約
58000のタンパク質、ローヤルゼリーの分子量5
−8万の画分、胎盤血画分を必要に応じ加え、用
いるなどのように行う。更に、ヒトラクトフエリ
ンなどの人乳成分および/または人乳と、要すれ
ばヒトの胎盤血画分を添加した培地でヒトの細胞
を培養する場合には、培地中の成分がすべてヒト
由来であることから、培地中に産生した有効物質
を完全に精製しなくともヒトに投与可能であると
いう利点を有する。
以下に実施例により本発明を説明する。
実施例 1
健康人の末梢リンパ球株細胞(Bri7)の105個
細胞を、第1表に示す添加物をD′MEM/F−12
(1:1)に添加した培地2mmに、植え込む。5
%CO2,37℃の条件下で3日間培養を行つた。得
られた結果は第1表に示すとおりである。
The present invention relates to a serum-free or low protein concentration medium for culturing animal cells or cells derived from animal cells, and relates to a fat culture medium characterized by containing milk and/or milk components. be. Animal cells and cells derived from animal cells are known to produce effective substances such as antibodies, interferon, insulin, and enzymes, and it is possible to obtain these effective substances by culturing these cells. being carried out or attempted. Traditionally, in order to culture these cells, it is almost always necessary to add serum to the culture medium. Fetal bovine serum, calf serum, etc. are generally used as serum, and the amount added is usually about 10%. However, these serums are expensive;
There are drawbacks such as inconsistent quality and limited supply. Furthermore, since serum contains a wide variety of components such as proteins, it is difficult to separate and purify effective substances from culture. As a result of repeated research to solve these problems, the present inventors discovered that cells can be grown in a serum-free medium with a low protein concentration, and have completed the present invention. Milk is, for example, human milk or animal milk (cow, goat, sheep, horse, etc.), and can be used regardless of whether it is colostrum or mature milk. A solution fraction obtained by centrifuging milk (hereinafter referred to as centrifuged milk solution fraction) is obtained by centrifuging milk at, for example, 20,000 x g. Molecular weight fractionation can be carried out using, for example, Sephadex G
−200 (Pharmacia Fine Chemicals) or
The gel filtration method is performed using Cellulofine GC-700 (Seikagaku Corporation) or the like. Equilibration and elution solutions used at that time include, for example, phosphate buffered saline, 100mM Na-Hepes buffer (PH
7.4), water, etc. Lactoferrin, for example
Lo¨nnerdal et al.'s method (Lo¨nnerdal, B., Carlsson,
J., and Porath, J. (1977) FEBS Lett.75, 89−
92). The cell culture medium of the present invention is used by adding these materials to a basal medium (not containing serum) used for normal animal cell culture. In addition, these milk and/or milk components,
Royal jelly and/or components of royal jelly, 1 from the fraction of placental blood with a molecular weight of 50,000 to 80,000
It is also possible to use seeds or more by adding them to the basal medium. The components of royal jelly are obtained as follows. The fraction of royal jelly with a molecular weight of 200,000 or more and the fraction with a molecular weight of 50,000 to 80,000 can be obtained in the same manner as the molecular weight fraction of milk. Royal jelly protein having a molecular weight of about 58,000 (hereinafter abbreviated as royal jelly protein) is purified, for example, as follows. Royal jelly is diluted twice with phosphate buffered saline and then dialyzed against it.
After dialysis, it is centrifuged at 20,000 x g, and the resulting supernatant is subjected to molecular weight fractionation in the same manner as for milk to obtain a molecular weight fraction of 50,000 to 80,000. After dialysis of this fraction against 1mM Tris-HCl buffer (PH8.0), Blue Sepharose (Pharmacia Fine
Chemicals) to obtain a flow-through fraction, that is, royal jelly protein. In addition, for the fraction of human placental blood with a molecular weight of 50,000 to 80,000 (hereinafter referred to as human placental blood fraction), for example, blood naturally exuded from the placenta is centrifuged at 20,000 x g, and the supernatant is further collected. Molecular weight fractionation can be performed by the method described above. As the basal medium of the culture medium of the present invention, any medium used for culturing general animal cells can be used. For example, Dulbecco's
Modified Eagle medium (hereinafter abbreviated as D'MEM),
Basal media such as F-12, RPMI-1640, insulin (2-10 μg/ml),
Selenium ( 10-11-10-8 M), transferrin (10-35 μg/ ml ), nucleic acid precursors (e.g. thymidine, hypoxanthine, etc., about 10-6 M), serum albumin (50-400 μg/ml), etc. A medium supplemented with can also be used as a basal medium. The milk added to the culture medium of the present invention is 0.1-5% (final protein concentration 7-350 μg/ml), preferably 0.5-5%.
It is desirable to keep it in the range of 2%. 7-350 μg/ml for the milk centrifugation solution fraction, 1-100 μg/ml for the fraction with a molecular weight of 200,000 or more, and a molecular weight of 4.
1-150 μg/ml for the −90,000 fraction and 0.5-50 μg/ml for lactoferrin. 10-300μ for other royal jelly, royal jelly components and placental blood fractions
g/ml is desirable. Although the culture medium of the present invention can be used for culturing animal cells such as fibroblasts and lymphoblastoid cells, it is most preferably used for culturing animal cell-derived cells such as lymphocyte-derived cells. Using the medium of the present invention, it is possible to obtain cell proliferation almost comparable to that of a conventional medium supplemented with a large amount of serum. In addition, it is cheaper than conventional media, and especially when milk and/or its components are used, culture can be performed very cheaply. In addition, compared to the protein concentration in the medium when 10% serum is added, which is 3 mg/ml or more, the medium of the present invention has a low protein concentration of 0.4 mg/ml or less, so it is effective for producing effective substances. By using the invented culture medium, it becomes easy to separate and purify the effective substance. Furthermore, since it is possible to add molecular weight fractions to the culture medium of the present invention, it can be used depending on the molecular weight of the effective substance. For example, when culturing cells that produce antibodies (molecular weight of 150,000 or more), lactoferrin and/or a fraction of milk with a molecular weight of 40,000 to 90,000 and, if necessary, a fraction with a molecular weight of about 40,000 to 90,000 separated and purified from royal jelly, are used.
58,000 proteins, the molecular weight of royal jelly is 5
-80,000 fraction and placental blood fraction are added and used as necessary. Furthermore, when culturing human cells in a medium supplemented with human milk components such as human lactoferrin and/or human milk and, if necessary, human placental blood fraction, all components in the medium are human-derived. Therefore, it has the advantage that the effective substance produced in the medium can be administered to humans without being completely purified. The present invention will be explained below with reference to Examples. Example 1 105 cells of a peripheral lymphocyte cell line (Bri7) from a healthy person were treated with D'MEM/F-12 with the additives shown in Table 1.
(1:1) in 2 mm of medium. 5
Culture was carried out for 3 days under conditions of % CO 2 and 37°C. The results obtained are shown in Table 1.
【表】
なおD′MEM/F−12に添加物としてヒトラク
トフエリン単独、ヒトラクトフエリンおよびロー
ヤルゼリータンパク質、ヒト血清アルブミンおよ
びラクトフエリン、ヒト血清アルブミンとラクト
フエリンおよびローヤルゼリータンパク質の4種
をそれぞれ加えた培地で30日間以上継代培養して
もそれぞれの増殖速度に変化がみられなかつた。
このことは永続的に継代培養することが可能であ
ることを示している。
実施例 2
Epstein−Barr Virusでトランスフオームした
ヒト由来のリンパ細胞(NL−matsumoto)につ
いて実施例1と同様にして培養を行う。得られた
結果は第2表に示す通りである。
第2表
添加物の
培 地 最終濃度 細胞数
(μg/ml) (個)
D′MEM/F−12 0.9×105
+ヒトラクトフエリン 10 7.4×105
+ヒト血清アルブミン 200 4.0×105
+ヒトラクトフエリン 10 7.8×105
+牛胎児血清、20% 6400 8.2×105 [Table] Four additives were added to D'MEM/F-12: human lactoferrin alone, human lactoferrin and royal jelly protein, human serum albumin and lactoferin, and human serum albumin and lactoferrin and royal jelly protein. No change was observed in the respective growth rates even after subculturing in the medium for 30 days or more.
This indicates that continuous subculture is possible. Example 2 Human-derived lymphocytes (NL-matsumoto) transformed with Epstein-Barr Virus are cultured in the same manner as in Example 1. The results obtained are shown in Table 2. Table 2 Media final concentration of additives Number of cells (μg/ml) (cells) D'MEM/F-12 0.9×10 5 + human lactoferrin 10 7.4×10 5 + human serum albumin 200 4.0×10 5 + Human lactoferrin 10 7.8×10 5 + Fetal bovine serum, 20% 6400 8.2×10 5
1 ローヤルゼリーを水若しくはリン酸緩衝化生
理食塩水で抽出した後透析した画分若しくはロー
ヤルゼリー蛋白質のうち分子量20万以上の画分若
しくは分子量5−9万の画分好ましくは分子量
58000の画分から選択したローヤルゼリーの成分
および/またはローヤルゼリーを含有することを
特徴とす細胞培養用培地。
2 ローヤルゼリーを水若しくはリン酸緩衝化生
理食塩水で抽出した後透析した画分またはローヤ
ルゼリー蛋白質の分子量20万以上の画分若しくは
分子量5−9万の画分好ましくは分子量58000の
画分から選択したローヤルゼリーの成分および/
またはローヤルゼリーと、乳を遠心分離して得ら
れる溶液画分、乳蛋白質の分子量20万以上の画分
若しくは分子量4−9万の画分またはラクトフエ
リンからなる乳の成分、乳、胎盤血の分子量5−
8万の画分から選択した添加成分とを含有するこ
とを特徴とす細胞培養用培地。
1. A fraction obtained by extracting royal jelly with water or phosphate buffered saline and then dialysis, or a fraction of royal jelly proteins with a molecular weight of 200,000 or more, or a fraction with a molecular weight of 50,000 to 90,000, preferably a molecular weight
1. A cell culture medium containing royal jelly components and/or royal jelly selected from 58,000 fractions. 2 Royal jelly selected from the fraction obtained by extracting royal jelly with water or phosphate buffered saline and then dialysis, or the fraction of royal jelly proteins with a molecular weight of 200,000 or more, or the fraction with a molecular weight of 50,000 to 90,000, preferably the fraction with a molecular weight of 58,000. ingredients and/or
Or royal jelly, a solution fraction obtained by centrifuging milk, a milk protein fraction with a molecular weight of 200,000 or more or a fraction with a molecular weight of 40,000 to 90,000, or milk components consisting of lactoferrin, milk, placental blood with a molecular weight of 5 −
A cell culture medium characterized by containing an additional component selected from 80,000 fractions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58041846A JPS59166079A (en) | 1983-03-14 | 1983-03-14 | Medium for cell culture |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58041846A JPS59166079A (en) | 1983-03-14 | 1983-03-14 | Medium for cell culture |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59166079A JPS59166079A (en) | 1984-09-19 |
| JPH0536026B2 true JPH0536026B2 (en) | 1993-05-28 |
Family
ID=12619614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58041846A Granted JPS59166079A (en) | 1983-03-14 | 1983-03-14 | Medium for cell culture |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59166079A (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59173078A (en) * | 1983-03-22 | 1984-09-29 | Morinaga & Co Ltd | Medium for cell culture |
| JPS59175876A (en) * | 1983-03-25 | 1984-10-04 | Morinaga & Co Ltd | Cell culture medium |
| DE3785102T2 (en) * | 1986-01-03 | 1993-07-22 | Genetics Inst | METHOD FOR PRODUCING FACTOR VIII: C TYPE PROTEINS. |
| KR102132457B1 (en) * | 2019-05-10 | 2020-07-09 | 주식회사 바이오솔루션 | Cell culture medium for culturing extracellular vesicles at a high concentration and a method for making conditioned medium containing a high level of extracellular vesicles using the cell culture medium |
-
1983
- 1983-03-14 JP JP58041846A patent/JPS59166079A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59166079A (en) | 1984-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gherardi et al. | Purification of scatter factor, a fibroblast-derived basic protein that modulates epithelial interactions and movement. | |
| Siegfried | Detection of human lung epithelial cell growth factors produced by a lung carcinoma cell line: use in culture of primary solid lung tumors | |
| JPH01503355A (en) | Use of interleukin-1 for guided differentiation of pluripotent hematopoietic cell populations | |
| Platzer et al. | Human pluripotent hemopoietic colony stimulating factor: activities on human and murine cells | |
| EP0061141B1 (en) | Chemokinesins and chemotaxins of leukocytes and inflamed tissues: natural mediator proteins for reversible promotion of random and directional locomotion (chemokinesis and chemotaxis) for accumulation of specific leukocyte types, process of their biotechnical preparation and pharmaceutical compositions | |
| US4613459A (en) | Lymphocyte growth factor | |
| JPH0536026B2 (en) | ||
| Hirai et al. | Isolation and partial purification of a new class of transforming growth factors from an avian sarcoma virus-transformed rat cell line | |
| KR920005920B1 (en) | New Cell Growth Regulator | |
| Savelkoul et al. | Semi-preparative purification and validation of monoclonal antibodies for immunotherapy in mice | |
| EP0061139A2 (en) | Mitogens of leukocytes and inflamed tissues: natural leukopoietic proteins for specific induction of proliferation and differentiation of leukocytes, process for their biotechnical preparation and pharmaceutical compositions | |
| WO1987006591A1 (en) | Immunosuppressive factor | |
| JPH0536027B2 (en) | ||
| WO1991018925A1 (en) | Novel megakaryocyte colony stimulating factor and production thereof | |
| JPH0543349B2 (en) | ||
| US5198356A (en) | Monophenotypic in vitro cell lines of megakaryocytic lineage, products produced thereby and methods | |
| US6331403B1 (en) | Use of mCRP to slow cell growth and to promote maturation of cells | |
| EP0148770B1 (en) | Composition for cell cultivation, production and use thereof | |
| Neumeier et al. | Two different types of granulocyte colony-stimulating factor produced by bovine lung tissue | |
| JP3133148B2 (en) | Human cellular fibronectin, its production method and cell line | |
| Tseng et al. | Development and characterization of a human B cell line that responds to B cell growth factor but not interleukin 2. | |
| JPH0216994A (en) | Cell growth inhibiting factor and production thereof | |
| JP3029635B2 (en) | Methods for obtaining antibody-producing mutants | |
| WO1994018310A1 (en) | Growth enhancing media supplement for the culture of mammalian cells | |
| Dodson et al. | Fibronectin and anchorage‐independent and anchorage‐dependent growth of benign and malignant cell lines |